Scholarlink

Background <p>Multiple Sclerosis (MS) severity is influenced by several factors. Understanding the impact of age at disease onset may help to better characterize clinical and disease features across age groups. This study aimed to characterize the clinical features and disability outcomes of late-onset MS (LOMS) and very late-onset MS (vLOMS), compared to adult-onset MS (AOMS).</p> Methods <p>We conducted an observational study using data from the MSBase registry and categorized patients based on age at MS onset: AOMS (18–39&#xa0;years), transition onset (40–49&#xa0;years), LOMS (50–59&#xa0;years), and vLOMS (≥ 60&#xa0;years). Disease progression was assessed using the 24&#xa0;week confirmed disability progression, EDSS4 and 6 milestones, conversion to secondary progressive MS(SPMS), and the first progression independent of relapse activity (PIRA) event. Cox proportional hazard regression models were used to determine unadjusted hazard ratios(HR), and propensity score inverse probability of treatment weighting(PS-IPTW) balanced covariate distributions.</p> Results <p>Among 81,236 patients, 5.2% had LOMS and 1% had vLOMS. Primary progressive MS was more frequent in LOMS and vLOMS (21.7 and 24%, respectively). Patients with LOMS and vLOMS had a significantly increased risk of 24&#xa0;week confirmed disability progression (HR:LOMS = 1.39, vLOMS = 1.80), EDSS 4 (HR:LOMS = 2.14, vLOMS = 2.95), EDSS 6 (HR:LOMS = 2.33, vLOMS = 6.33), SPMS (HR:LOMS = 1.62, vLOMS = 2.38), and first PIRA event (HR:LOMS = 2.12, vLOMS = 2.93).</p> Conclusion <p>LOMS and vLOMS exhibited a more progressive disease onset and higher disability milestones compared with AOMS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

  • 期刊论文

  • 发表日期：

    2026年2月4日

查看全文
  • Amira Souissi,
  • Francesco Patti,
  • Tim Spelman,
  • Clara Chisari,
  • Amina Gargouri,
  • Nevin John,
  • Allan G. Kermode,
  • Tomas Kalincik,
  • Helmut Butzkueven,
  • Seyed Aidin Sajedi,
  • Jeannette Lechner-Scott,
  • Izanne Roos,
  • Guy Laureys,
  • Bruce Taylor,
  • Raed Alroughani,
  • Samia J. Khoury,
  • Richard Macdonell,
  • Bianca Weinstock-Guttman,
  • Eva Kubala Havrdova,
  • Davide Maimone,
  • Stephen Reddel,
  • Marzena Fabis-Pedrini,
  • Barbara Willekens,
  • Abdorreza Naser Moghadasi,
  • Patrice Lalive,
  • Alessandra Lugaresi,
  • Serkan Ozakbas,
  • Claudio Solaro,
  • Simón Cárdenas-Robledo,
  • Vahid Shaygannejad,
  • Masoud Etemadifar,
  • Cavit Boz,
  • Sara Eichau,
  • Valentina Tomassini,
  • Murat Terzi,
  • Alexandre Prat,
  • Mario Habek,
  • Yolanda Blanco,
  • Ayse Altintas,
  • Oliver Gerlach,
  • Recai Turkoglu,
  • Katherine Buzzard,
  • Olga Skibina,
  • Aysun Soysal,
  • Anneke van der Walt,
  • Stella Hughes,
  • Vincent van Pesch,
  • Matteo Foschi,
  • Andrea Surcinelli,
  • Julie Prevost,
  • Cristina Ramo-Tello,
  • Chris McGuigan,
  • Maria Jose Sa,
  • Jens Kuhle,
  • Daniele Spitaleri,
  • Bhim Singhal,
  • Radek Ampapa,
  • Koen de Gans,
  • Thor Petersen,
  • Mihaela Simu,
  • Emmanuelle Lapointe,
  • Jose Luis Sanchez-Menoyo,
  • Orla Gray,
  • Justin Garber,
  • Eduardo Aguera-Morales,
  • Katrin Gross-Paju,
  • Tamara Castillo-Triviño,
  • Abdullah Al-Asmi,
  • Nikolaos Grigoriadis,
  • Jihad Inshasi,
  • Talal Al-Harbi,
  • Todd A. Hardy,
  • Sudarshini Ramanathan,
  • Melissa Cambron,
  • Neil Shuey,
  • Angel Perez sempere,
  • Tunde Csepany,
  • Irene Treviño-Frenk,
  • Csilla Rozsa,
  • Marija Cauchi,
  • Rana Karabudak,
  • Saloua Mrabet,
  • Riadh Gouider

摘要

Background

Multiple Sclerosis (MS) severity is influenced by several factors. Understanding the impact of age at disease onset may help to better characterize clinical and disease features across age groups. This study aimed to characterize the clinical features and disability outcomes of late-onset MS (LOMS) and very late-onset MS (vLOMS), compared to adult-onset MS (AOMS).

Methods

We conducted an observational study using data from the MSBase registry and categorized patients based on age at MS onset: AOMS (18–39 years), transition onset (40–49 years), LOMS (50–59 years), and vLOMS (≥ 60 years). Disease progression was assessed using the 24 week confirmed disability progression, EDSS4 and 6 milestones, conversion to secondary progressive MS(SPMS), and the first progression independent of relapse activity (PIRA) event. Cox proportional hazard regression models were used to determine unadjusted hazard ratios(HR), and propensity score inverse probability of treatment weighting(PS-IPTW) balanced covariate distributions.

Results

Among 81,236 patients, 5.2% had LOMS and 1% had vLOMS. Primary progressive MS was more frequent in LOMS and vLOMS (21.7 and 24%, respectively). Patients with LOMS and vLOMS had a significantly increased risk of 24 week confirmed disability progression (HR:LOMS = 1.39, vLOMS = 1.80), EDSS 4 (HR:LOMS = 2.14, vLOMS = 2.95), EDSS 6 (HR:LOMS = 2.33, vLOMS = 6.33), SPMS (HR:LOMS = 1.62, vLOMS = 2.38), and first PIRA event (HR:LOMS = 2.12, vLOMS = 2.93).

Conclusion

LOMS and vLOMS exhibited a more progressive disease onset and higher disability milestones compared with AOMS.